世界および米国における King Pharmaceuticals 社の動向：2005 年版

Introduction

This analysis examines the current position and future outlook for King in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

• Benchmark Kings performance against key rivals in the ethical pharmaceutical sector
• Evaluate the impact of Kings recent divestment of its womens health business
• Understand the key drivers and resistors of Kings growth to 2010

CHAPTER 1 EXECUTIVE SUMMARY

• Key findings
• Strategic outlook
• Current positioning: competitive outlook 2004
• Datamonitors strategic recommendations
• Key issues facing King Pharmaceuticals: 2005-10
• King Pharmaceuticals forecast revenue stream, 2005-10

CHAPTER 2 GLOBAL COMPANY STRATEGY

• Introduction to King Pharmaceuticals
• Assessment of strategic position
• Strengths
• Weaknesses
• Opportunities
• Threats
• Datamonitors strategic recommendations
• Therapeutic foci
• Evolution of R&D focus
• Growth strategy assessment
• Organic growth
• Partnerships/licensing
• Mergers and acquisitions
• Mylans failed acquisition
• Corporate alliances and deals
• Elan
• Palatin Technologies
• Novavax
• Salix Pharmaceuticals

CHAPTER 3 GLOBAL PORTFOLIO AND PIPELINE ANALYSIS

• Evolution of therapy area focus, 2004-10
• Key growth drivers/resistors
• Cardiovascular franchise
• Marketed products
• Altace (ramipril)
• Thrombin-JMI (thrombin)
• Adenoscan (adenosine) and Adenocard (adenosine)
• R&D compounds
• Binodenoson (MRE-470)
• Cardiovascular portfolio sales forecasts and forecast revenue growth
• CNS franchise
• Marketed products
• Skelaxin (metaxalone)
• Sonata (zaleplon)
• R&D compounds
• T-62
• Diaject (diazepam)
• CNS portfolio sales forecasts and forecast revenue growth
• Diabetes and endocrinology franchise
• Marketed products
• Levoxyl (levothyroxine sodium)
• Cytomel/Triostat (liothyronine)
• R&D compounds
• MRE0094
• Diabetes and Endocrinology portfolio sales forecasts and forecast revenue growth
• Infectious disease franchise
• Marketed products
• Bicillin (penicillin G benzathine)
• Synercid (quinupristin/dalfopristin)
• R&D compounds
• Infectious disease portfolio sales forecasts and forecast revenue growth
• Other products
• Marketed products
• Intal (sodium cromoglycate)
• Tilade (nedocromil sodium)
• R&D compounds
• PT-141
• Other products sales forecasts and forecast revenue growth

CHAPTER 4 US STRATEGY, PORTFOLIO AND PIPELINE

CHAPTER 5 CORPORATE DEVELOPMENT

• Financial position, 2003-04
• Financial position, 2003-04
• Profitability, 2000-04
• Revenue growth
• Cost structure
• Net Loss for 2004
• Liquidity, 2000-04
• 2004 performance benchmarking
• Business model clustering according to 2004 cost ratios
• 2004 growth and investment momentum

CHAPTER 6 APPENDIX : SUPPORTING DATA

• Financial data
• Exchange rates
• Methodology for therapy area forecasting
• List of Tables
• Table 1: Summary of Kings historical agreements, 2004-05
• Table 2: Breakdown of King Pharmaceuticals ethical sales by therapy area, 2004-10
• Table 3: Kings marketed cardiovascular portfolio
• Table 4: The leading US ACE inhibitor branded treatments for hypertension
• Table 5: Kings current cardiovascular R&D pipeline, 2004
• Table 6: Forecast sales for Kings cardiovascular portfolio, 2005-10
• Table 7: King Pharmaceuticals marketed CNS portfolio
• Table 8: King Pharmaceuticals CNS R&D pipeline, 2005
• Table 9: Forecast sales for Kings CNS portfolio, 2005-10
• Table 10: King Pharmaceuticals marketed diabetes and endocrinology portfolio
• Table 11: King Pharmaceuticals Diabetes and Endocrinology pipeline, 2005
• Table 12: Forecast sales for Kings diabetes and endocrinology portfolio, 2005-10
• Table 13: King Pharmaceuticals marketed infectious disease portfolio
• Table 14: King Pharmaceuticals infectious disease R&D pipeline, 2005
• Table 15: Forecast sales for Kings infectious disease portfolio, 2005-10
• Table 16: King Pharmaceuticals other marketed products
• Table 17: Kings current other R&D products
• Table 18: Forecast sales of King Pharmaceuticals other products portfolio, 2005-10
• Table 19: King Pharmaceuticals revenues by division, 2003-2004
• Table 20: King Pharmaceuticals expenses, 2003-2004
• Table 21: Exchange rates*, 2004
• List of Figures
• Figure 1: SWOT analysis for King Pharmaceuticals
• Figure 2: Competitive positioning of King Pharmaceuticals within the pharmaceutical market, 2004
• Figure 3: Forecast sales for King Pharmaceuticals major therapy areas, 2005-2010
• Figure 4: King Pharmaceuticals level of generic threat by therapy area to 2010
• Figure 5: Development of King Pharmaceuticals therapeutic strategy, 2005-10
• Figure 6: King Pharmaceuticals business development by therapy area
• Figure 7: King Pharmaceuticals ethical sales breakdown, 2004 and 2010 (forecast)
• Figure 8: King Pharmaceuticals growth drivers and resistors, 2005-10
• Figure 9: King Pharmaceuticals profitability stream, 2000-2004
• Figure 10: Kings liquid assets versus total liabilities, 2000-2004
• Figure 11: R&D and S,G&A spend and COGS as a proportion of sales, 2004
• Figure 12: Benchmarking of financial strength, 2004